Soluble HER2 (sHER2) levels in HER2-positive breast cancer patients receiving chemotherapy ± trastuzumab: Results from the NCCTG adjuvant trial N9831

PURPOSE: IncreasedsHER2 is an indicator of poor prognosisin HER2+ metastatic breast cancer. This study evaluated the levels of sHER2 during treatment and at time of recurrence in the adjuvant N9831 clinical trial. PATIENTS AND METHODS: Aims were to describe sHER2 levels during treatment and at time...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Moreno-Aspitia, A., Hillman, D. W., Dyar, S. H., Tenner, K. S., Gralow, J., Kaufman, P. A., Davidson, N. E., Lafky, J. M., Reinholz, M. M., Lingle, W. L., Kutteh, L. A., Carney, W. P., Dueck, A. C., Perez, E. A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4126833/
https://ncbi.nlm.nih.gov/pubmed/23744760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28130
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares